Talk to the Veterans Crisis Line now
U.S. flag
An official website of the United States government

VA Health Systems Research

Go to the VA ORD website
Go to the QUERI website

HSR Citation Abstract

Search | Search by Center | Search by Source | Keywords in Title

Cost utility of inflammation-targeted therapy for patients with ulcerative colitis.

Saini SD, Waljee AK, Higgins PD. Cost utility of inflammation-targeted therapy for patients with ulcerative colitis. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association. 2012 Oct 1; 10(10):1143-51.

Dimensions for VA is a web-based tool available to VA staff that enables detailed searches of published research and research projects.

If you have VA-Intranet access, click here for more information

VA staff not currently on the VA network can access Dimensions by registering for an account using their VA email address.
   Search Dimensions for VA for this citation
* Don't have VA-internal network access or a VA email address? Try searching the free-to-the-public version of Dimensions


BACKGROUND and AIMS: Oral mesalamine drugs are frequently used to treat patients with mild-to-moderate ulcerative colitis (UC). However, these drugs are costly, and long-term adherence is poor. We compared the cost utility of inflammation-targeted, intermittent therapy with that of universal, continuous maintenance therapy with mesalamine agents for patients with mild-to-moderate UC. METHODS: We developed a Markov cohort model that simulated a population of adult patients with newly diagnosed, quiescent UC after induction of remission with mesalamine agents. We obtained model inputs from the literature. The perspective taken was that of a short-term payer (health insurance provider) during a 5-year time period. We modeled 3 treatment strategies: symptom-targeted treatment (treatment for symptomatic disease flares only, SYMPT), continuous mesalamine maintenance for all patients (CONT, the current standard of care), and inflammation-targeted treatment (mesalamine therapy for only patients with a stool sample positive for an inflammatory marker, INFLAM). We measured disease flares, quality-adjusted life years (QALYs), costs (2009 U.S. dollars), and incremental cost-effectiveness ratios. RESULTS: INFLAM was the least costly strategy (cumulative per-patient cost of $22,798), compared with $24,378 for the SYMPT and $25,621 for the CONT strategies. Despite the lower cost, INFLAM was comparable to SYMPT and CONT in effectiveness (4.4986 vs 4.5014 QALYs, respectively), making INFLAM the optimal strategy. Several variables were found to be important in sensitivity analysis; the CONT strategy was optimal only if the cost of mesalamine drugs was markedly reduced. CONCLUSIONS: Inflammation-targeted treatment of patients with UC is effective and costs less than continuous treatment of all patients with mesalamine, the current standard of care. Prospective trials of inflammation-targeted treatment are warranted.

Questions about the HSR website? Email the Web Team

Any health information on this website is strictly for informational purposes and is not intended as medical advice. It should not be used to diagnose or treat any condition.